T0	Participants 45 93	children with pervasive developmental disorders:
T1	Participants 209 257	children with pervasive developmental disorders.
T2	Participants 265 508	Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment with risperidone as part of a previously described controlled discontinuation study
T3	Participants 1475 1523	children with pervasive developmental disorders.